Brenetafusp
- Generic Name
- Brenetafusp
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3
Recruiting
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 680
- Registration Number
- NCT06112314
- Locations
- 🇧🇷
Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor, Barretos, Brazil
🇧🇷Centro de Pesquisas Oncologicas (CEPON), Florianópolis, Brazil
🇧🇷Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Hospital Sao Lucas - Centro de Pesquisa Clinica (CPC), Porto Alegre, Brazil
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Phase 1
Recruiting
- Conditions
- Select Advanced Solid Tumors
- Interventions
- Drug: Brenetafusp and chemotherapyDrug: Brenetafusp and monoclonal antibodies and chemotherapyDrug: Brenetafusp and bevacizumabDrug: Brenetafusp and kinase inhibitors
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Immunocore Ltd
- Target Recruit Count
- 727
- Registration Number
- NCT04262466
- Locations
- 🇵🇱
Centrum Medyczne Pratia Poznan - Skorzewo, Skórzewo, Poland
🇵🇱Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland
🇪🇸Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona, Navarra, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath